Exelixis (EXEL) Share-based Compensation (2010 - 2026)
Exelixis (EXEL) posted quarterly Share-based Compensation of $34.2 million for Q2 2026, up 52.03% year-over-year from $22.5 million in Q2 2025, and up 70.33% quarter-over-quarter from $20.1 million in Q1 2026.
Exelixis (EXEL) Share-based Compensation (2010 - 2026) Analysis & Trends
Exelixis' Share-based Compensation history runs 17 years deep, the most recent figure standing at $34.2 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 52.03% year-over-year to $34.2 million; the TTM figure through Apr 2026 stood at $124.7 million (up 566.26% YoY), while the FY2026 annual figure was $113.0 million, up 637.82% from the prior year.
- Share-based Compensation for Q2 2026 stood at $34.2 million, up from $20.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $91.5 million in Q4 2022, with the low at -$52.2 million in Q1 2025.
- The 5-year median for Share-based Compensation is $19.1 million (2024), against an average of $16.9 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation tumbled 1468.43% in 2022, then jumped 4282.35% in 2025.
- Exelixis' Share-based Compensation stood at $91.5 million in 2022, then slumped by 107.12% to -$6.5 million in 2023, then soared by 828.94% to $47.5 million in 2024, then plunged by 34.95% to $30.9 million in 2025, then advanced by 10.83% to $34.2 million in 2026.
- Business Quant data shows EXEL's Share-based Compensation at $34.2 million in Q2 2026, $20.1 million in Q1 2026, and $30.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 36.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 36.34 Mn |
| Jul 3, 2026 | 36.34 Mn |
| Apr 3, 2026 | 34.23 Mn |
| Apr 3, 2026 | 34.23 Mn |
| Jan 2, 2026 | 20.10 Mn |
| Jan 2, 2026 | 20.10 Mn |
| Oct 3, 2025 | 30.89 Mn |
| Oct 3, 2025 | 30.89 Mn |
| Jul 4, 2025 | 39.49 Mn |
| Jul 4, 2025 | 39.49 Mn |
| Apr 4, 2025 | 22.52 Mn |
| Apr 4, 2025 | 22.52 Mn |
| Jan 3, 2025 | -52.18 Mn |
| Jan 3, 2025 | -52.18 Mn |
| Sep 27, 2024 | 47.48 Mn |
| Sep 27, 2024 | 47.48 Mn |
| Jun 28, 2024 | 901,000.00 |
| Jun 28, 2024 | 901,000.00 |
| Mar 29, 2024 | 19.11 Mn |
| Mar 29, 2024 | 19.11 Mn |